Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 3/20 | 0.67 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | MMP14 | P50281 | 1/20 | 0.63 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13174129 | 0.95 | SPPL2A (0.61) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL5945539 | 0.95 | SPPL2A (0.61) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL7419618 | 0.92 | SPPL2A (0.67) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL14602719 | 0.89 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL1058690 | 0.89 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL7905239 | 0.89 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL13537788 | 0.89 | SPPL2A (0.58) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL1054059 | 0.88 | SPPL2A (0.73) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL13537905 | 0.88 | SPPL2A (0.58) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL4911140 | 0.88 | SPPL2A (0.76) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2216334-B1 | HIV protease inhibiting sulfonamides | ABBOTT LAB (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2264032-A2 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2216334-A1 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-1709037-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LAB (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1709037-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005061450-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | SPPL2A 1106/4885ADAMTS4 232/4885MMP2 19/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | SPPL2A 1106/4885ADAMTS4 232/4885MMP2 19/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | SPPL2A 1106/4885ADAMTS4 232/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.